Lv1
40 积分 2025-10-13 加入
Degrader–Antibody Conjugates: Emerging New Modality
13小时前
已完结
What influences the activity of Degrader−Antibody conjugates (DACs)
8天前
已完结
Rational Design of Dual Degraders by Incorporating Molecular Glue Structural Features into PROTAC Degraders
13天前
已完结
Inhibition of KAT6A enhances immunotherapy efficacy in colorectal cancer by activating interferon response
2个月前
已完结
KAT7 enhances the proliferation and metastasis of head and neck squamous carcinoma by promoting the acetylation level of LDHA
3个月前
已完结
Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro
3个月前
已完结
Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis
3个月前
已完结
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
3个月前
已完结
Discovery of BRD9 Molecular Glue Degraders That Spare Cardiomyocytes
4个月前
已完结
Dual KAT6/7 inhibition delivers robust monotherapy anti-tumor activity in biomarker selected indications and disrupts emergence of drug-tolerant persister cell populations
5个月前
已关闭
皖公网安备34019202002308
